pharmaphorum1mon
Gilead, MSD say HIV combo could be weekly, oral HIV drug
In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose ... 1.9% of the Biktarvy group. "Daily single-tablet regimens ...
Business Wire20d
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
At HIV Glasgow, presented study results and analyses will include further evaluation of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF ...